ReviewImmunogenetics2012
TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition.
Review in Immunogenetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- Minor histocompatibility antigen TCR-T.Blood advances · 2026Review
- Quantitative and large-scale investigation of human TCR-HLA cross-reactivity.Science advances · 2025Article
- epiArt: a graphical HLA eplet amino acid repertoire translation reveals the need for an epitope driven revision of allele group nomenclature.Frontiers in genetics · 2024Article
- TCR Sequencing in Mouse Models of Allorecognition Unveils the Features of Directly and Indirectly Activated Clonotypes.International journal of molecular sciences · 2023Article
- Hurdles to breakthrough in CAR T cell therapy of solid tumors.Stem cell research & therapy · 2022Review
- Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.Frontiers in oncology · 2022Review
- A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.Stem cell research & therapy · 2021Review
- Critical role of the CD44Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.Journal for immunotherapy of cancer · 2021Article
- Analysis of T-Cell Receptor Repertoire in Transplantation: Fingerprint of T Cell-mediated Alloresponse.Frontiers in immunology · 2021Review
- HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation.Frontiers in immunology · 2021Review
- T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.Frontiers in immunology · 2020Review
- The TreaT-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome.Scientific reports · 2019Article
- Single blood transfusion induces the production of donor-specific alloantibodies and regulatory T cells mainly in the spleen.International immunology · 2018Article
- Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms.Immunogenetics · 2017Review
- Immunological challenges associated with artificial skin grafts: available solutions and stem cells in future design of synthetic skin.Journal of biological engineering · 2017Review
- Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.Frontiers in immunology · 2017Article
- IL-21 Receptor Antagonist Inhibits Differentiation of B Cells toward Plasmablasts upon Alloantigen Stimulation.Frontiers in immunology · 2017Article
- Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection.BMC nephrology · 2016Article
- A New Window into the Human Alloresponse.Transplantation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alloreactive T cells are core mediators of graft rejection and are a potent barrier to transplantation tolerance. It was previously unclear how T cells educated in the recipient thymus could recognize allogeneic HLA molecules. Recently it was shown that both naïve and memory CD4+ and CD8+ T cells are frequently cross-reactive against allogeneic HLA molecules and that this allorecognition exhibits exquisite peptide and HLA specificity and is dependent on both public and private specificities of the T cell receptor. In this review we highlight new insights gained into the immunogenetics of allorecognition, with particular emphasis on how viral infection and vaccination may specifically activate allo-HLA reactive T cells. We also briefly discuss the potential for virus-specific T cell infusions to produce GvHD. The progress made in understanding the molecular basis of allograft rejection will hopefully be translated into improved allograft function and/or survival, and eventually tolerance induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.